Effects and safety of immunosuppressor combined with corticosteroid on Henoch-Sch?nlein purpura nephritis: a Meta-analysis
10.3760/cma.j.issn.1673-4912.2021.09.009
- VernacularTitle:免疫抑制剂联合激素治疗紫癜性肾炎疗效和安全性的Meta分析
- Author:
Zhongbin TAO
1
;
Yandong FENG
;
Jie WANG
;
Yongkang ZHOU
;
Xiaoli YAN
;
Jia YAO
;
Yiqing WANG
;
Bowen LI
;
Jizu LING
;
Xinhui YUAN
Author Information
1. 兰州大学第一医院儿科 730000
- Keywords:
Immunosuppressive agents;
Henoch-Sch?nlein purpuranephritis;
Meta-analysis
- From:
Chinese Pediatric Emergency Medicine
2021;28(9):785-792
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To assess the efficacy of immunosuppressor on treatment of Henoch-Sch?nlein purpura nephritis(HSPN).Methods:Literatures were searched in PubMed, Cochrane library, Web of Science, Wanfang database, CNKI and CBM database from inception to January 2021.The studies that investigated the effect of immunosuppressor on HSPN outcomes were included.Article screening, data extraction and quality assessment were accomplished by two investigators independently, and statistical analyses were performed by STATA 14.Results:Ten studies were included with 443 cases, of which, 245 cases were in the experimental group while 198 cases were in the control group.The Meta-analysis showed that the experimental group had higher complete remission rate( OR=1.95, 95% CI 1.19-3.22, P=0.009), total remission rate ( OR=2.92, 95% CI 1.74-4.88, P<0.001), proteinuria decreasing level ( SMD=0.35, 95% CI 0.09-0.61, P=0.008), the increasing level of serum albumin ( SMD=1.27, 95% CI 0.43-2.11, P=0.003) and the increasing level of estimated glomerular filtration rate ( SMD=0.48, 95% CI 0.21-0.76, P=0.001), lower relapse rate ( OR=0.19, 95% CI 0.05-0.72, P=0.015) as well as death rate ( OR=0.19, 95% CI 0.04-0.78, P=0.021)than those of the control group. Conclusion:The immunosuppressor could enhance complete remission rate, total remission rate, proteinuria decreasing level, the increasing level of serum albumin and the increasing level of estimated glomerular filtration rate, reduce relapse rate and death rate of HSPN patients.
